5 completed, 1 unknown. 6 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 5, Unknown 1 |
| Phase 2 | 4 | Completed 3, Unknown 1 |
Follow SARS CoV 2 Infection: new trials by email Literature Review of SARS CoV 2 Infection trials Research Report on SARS CoV 2 Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines NVX-CoV2515, NVX-Cov2373, NVX-CoV2373 + NVX-CoV2515 - COVID-19, SARS CoV 2 Infection | Phase 3 | Completed | Novavax | 1340 | 2022-05-25 | 2024-04-23 |
| Inhibition of Bradykinin in COVID-19 Infection With Icatibant Icatibant, 0.9% Sodium Chloride Injection - SARS CoV 2 Infection | Phase 2 / Phase 3 | Completed | Belfast Health and Social Care Trust | 32 | 2022-05-16 | 2023-09-07 |
| A Phase IIb/III Clinical Trial to Assess Safety and Immunogenicity of a COVID-19 Vaccine Booster Dose in Immunosupressed Adults. PHH-1V - SARS CoV 2 Infection | Phase 2 / Phase 3 | Completed | Hipra Scientific, S.L.U | 241 | 2022-05-12 | 2025-09-16 |
| Sisonke 2 - A COVID-19 Vaccine Boost Open Label Study. Sisonke Heterologous mRNA-1273 boost after prime with Ad26.COV2.S - SARS CoV 2 Infection | Phase 3 | Completed | Wits Health Consortium (Pty) Ltd | 500000 | 2021-11-10 | 2026-09-01 |
| PROSPECTIVE OPEN LABEL CLINICAL TRIAL TO ADMINISTER A BOOSTER DOSE OF PFIZER/BIONTECH OR MODERNA COVID-19 VACCINE IN HIGH-RISK INDIVIDUALS Pfizer/BioNTech (BNT162b2), Moderna - SARS CoV 2 Infection, COVID-19 | Phase 2 / Phase 3 | Unknown | DHR Health Institute for Research and Development | 1000 | 2021-07-30 | 2022-03-29 |
| Multicenter Double Blind, Parallel-group Phase 2/3 Trial, to Study Raloxifene in Adult COVID-19 Patients. Raloxifene, Placebo - SARS CoV 2 Infection | Phase 2 / Phase 3 | Completed | Dompé Farmaceutici S.p.A | 61 | 2021-01-22 | 2023-12-26 |
COVID-19 (6) · Coronavirus Infections (1) · Pneumonia (1)
Coronaviridae Infections (6) · Infections (6) · Lung Diseases (6) · Nidovirales Infections (6) · Pneumonia, Viral (6) · RNA Virus Infections (6) · Respiratory Tract Diseases (6) · Respiratory Tract Infections (6) · Virus Diseases (6) · Coronavirus Infections (5) · Pneumonia (5)
2019-nCoV Vaccine mRNA-1273 (1) · Ad26COVS1 (1) · BNT162 Vaccine (1) · HIPRA COVID-19 vaccine (1) · NVX-CoV2373 adjuvated lipid nanoparticle (1) · Raloxifene Hydrochloride (1) · Sodium Chloride (1) · icatibant (1)
Belfast Health and Social Care Trust (1) · DHR Health Institute for Research and Development (1) · Dompé Farmaceutici S.p.A (1) · Hipra Scientific, S.L.U (1) · Novavax (1) · Wits Health Consortium (Pty) Ltd (1)
Spain (2) · Australia (1) · France (1) · Italy (1) · South Africa (1) · Turkey (Türkiye) (1) · United Kingdom (1) · United States (1)
Francesco Sergio, MD, PhD (1) · Glenda Gray, MBChB (1) · Joe Kidney, MD (1) · Sohail Rao, MD,MA,DPhil (1)
PMID 35582123, PMID 38035747, PMID 38278629, PMID 38460525, PMID 39052718